OBJECTIVE: Restenosis is a major limitation of percutaneous coronary intervention. Migration and proliferation of vascular cells remain a cornerstone in neointimal formation. The cardioprotection of estrogen is well recognized, but the intracellular mechanisms related to these beneficial effects are not completely understood. METHODS AND RESULTS: We investigated the effects of 17beta-estradiol (17betaE) on mitogen-activated protein kinase (MAPK) activity and the migration and proliferation of porcine aortic endothelial cells (PAECs) and porcine smooth muscle cells (PSMCs). Treatment with 17betaE (10(-8) mol/L) abrogated p38 and p42/44 MAPK phosphorylation mediated by platelet-derived growth factor-BB as well as the migration and proliferation of PSMCs. In contrast, treatment with 17betaE (10(-8) mol/L) induced the phosphorylation of p38 and p42/44 MAPK and the migration and proliferation of PAECs. Interestingly, the effects of 17betaE on PSMCs and PAECs were reversed by selective estrogen receptor antagonists (tamoxifen, 4-OH-tamoxifen, and raloxifen). These results suggest that in PSMCs, 17betaE inhibits chemotactic and mitogenic effects of platelet-derived growth factor-BB as well as p38 and p42/44 MAPK phosphorylation. In contrast, 17betaE promotes in PAECs the phosphorylation of p42/44 and p38 MAPK as well as the migration and proliferation of these cells. CONCLUSIONS: Treatment with 17betaE has a dual beneficial effect: the improvement of vascular healing and the prevention of restenosis after angioplasty.
OBJECTIVE:Restenosis is a major limitation of percutaneous coronary intervention. Migration and proliferation of vascular cells remain a cornerstone in neointimal formation. The cardioprotection of estrogen is well recognized, but the intracellular mechanisms related to these beneficial effects are not completely understood. METHODS AND RESULTS: We investigated the effects of 17beta-estradiol (17betaE) on mitogen-activated protein kinase (MAPK) activity and the migration and proliferation of porcine aortic endothelial cells (PAECs) and porcine smooth muscle cells (PSMCs). Treatment with 17betaE (10(-8) mol/L) abrogated p38 and p42/44 MAPK phosphorylation mediated by platelet-derived growth factor-BB as well as the migration and proliferation of PSMCs. In contrast, treatment with 17betaE (10(-8) mol/L) induced the phosphorylation of p38 and p42/44 MAPK and the migration and proliferation of PAECs. Interestingly, the effects of 17betaE on PSMCs and PAECs were reversed by selective estrogen receptor antagonists (tamoxifen, 4-OH-tamoxifen, and raloxifen). These results suggest that in PSMCs, 17betaE inhibits chemotactic and mitogenic effects of platelet-derived growth factor-BB as well as p38 and p42/44 MAPK phosphorylation. In contrast, 17betaE promotes in PAECs the phosphorylation of p42/44 and p38 MAPK as well as the migration and proliferation of these cells. CONCLUSIONS: Treatment with 17betaE has a dual beneficial effect: the improvement of vascular healing and the prevention of restenosis after angioplasty.
Authors: Melissa E Hogg; Vinit N Varu; Ashley K Vavra; Daniel A Popowich; Monisha N Banerjee; Janet Martinez; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe Journal: Free Radic Biol Med Date: 2011-01-21 Impact factor: 7.376
Authors: Vincent Fontaine; Cédric Filipe; Nikos Werner; Pierre Gourdy; Audrey Billon; Barbara Garmy-Susini; Laurent Brouchet; Francis Bayard; Hervé Prats; Thomas Doetschman; Georg Nickenig; Jean-François Arnal Journal: Am J Pathol Date: 2006-11 Impact factor: 4.307
Authors: Guillermo N Armaiz-Pena; Lingegowda S Mangala; Whitney A Spannuth; Yvonne G Lin; Nicholas B Jennings; Alpa M Nick; Robert R Langley; Rosemarie Schmandt; Susan K Lutgendorf; Steven W Cole; Anil K Sood Journal: Clin Cancer Res Date: 2009-04-21 Impact factor: 12.531
Authors: Dongmin Liu; Mary Iruthayanathan; Laurie L Homan; Yiqiang Wang; Lingling Yang; Yao Wang; Joseph S Dillon Journal: Endocrinology Date: 2007-12-13 Impact factor: 4.736